Compare Teucrium Corn Fund (CORN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teucrium Corn Fund vs Recursion Pharmaceuticals Inc — how do they compare? Teucrium Corn Fund trades at $17.53, while Recursion Pharmaceuticals Inc trades at $3.32 (market cap $1.78B). The key difference: Teucrium Corn Fund is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CORN | RXRX | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $19.12 | $6.79 |
52-Week Low | $16.46 | $2.84 |
Market Cap | — | $1.78B |
Enterprise Value | — | $1.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CORN trades at $17.64, up 0.17% for the day, with technical indicators showing a bearish bias from moving averages despite a neutral oscillator stance and oversold short-term RSI. Recent news highlights strong performance in agricultural ETFs, with CORN returning 9.7% over the past month, driven by inflation trends and geopolitical tensions affecting commodity markets.
The outlook is mixed; positive momentum from commodity strength offers upside, but bearish technicals and reliance on volatile agricultural markets pose risks. Investors should weigh near-term commodity tailwinds against the absence of fundamental financial data and broader market sentiment shifts.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Teucrium Corn Fund
CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.
Read more on CORN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
